By NewsDesk  @bactiman63 Vaccine company, Valneva, announced Monday positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553. Following...

Vaccine company, Valneva, announced that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya...

Specialty vaccine company, Valneva, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation for its single-shot Phase 3 chikungunya vaccine candidate...

Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the initiation of a pivotal Phase 3 clinical trial for its differentiated, single-shot...

Valneva SE, a specialty vaccine company, announced today the publication of full data from the Phase 1 clinical trial of its chikungunya vaccine candidate, VLA1553, in the peer-reviewed medical journal The...

Valneva SE announced this week that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and agreed on the clinical development plan towards licensure...

Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced excellent final Phase 1 results for its single-shot chikungunya...

In a follow-up on Valneva’s Chikungunya vaccine candidate, the France based biotech company announced Friday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...

Valneva SE, a commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced progress in its Phase 1 program targeting a single-shot vaccine against Chikungunya.  The...

Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, announced the initiation of a Phase I clinical trial in the U.S. to evaluate the safety...